Monoclonal antibody · Kills target cells, directed at primate-restricted N-linked carbohydrate epitope (glycotope) on human carcinomas · developed by MacroGenics
RAV12 is a chimeric monoclonal antibody that binds a primate-restricted N-linked carbohydrate epitope expressed on various human carcinomas. After binding, it disrupts sodium channels of the tumor cells, causing cell and organelle swelling and cell death. It has been studied in cancers including pancreatic cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00625586 | Phase 2 | Pancreatic Cancer | Terminated | MGNX |
| NCT00101972 | Phase 1 | Cancer | Completed | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerPancreatic Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →